ClinicaliQ Trial Snapshot
- Open-label Extension Study of GB002 in Adult Subjects With Pulmonary Arterial Hypertension (PAH) — Active Not Recruiting • Phase II • Cardiology / Cardiovascular • NCT04816604.
- Long-term safety and effectiveness study of seralutinib, a new drug treatment, in adults with pulmonary arterial hypertension.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
This open-label extension study will evaluate the long-term effects of GB002 (seralutinib) in subjects who previously participated in a GB002 PAH study. Conditions: Pulmonary Arterial Hypertension Interventions: GB002 (seralutinib), Generic Dry Powder Inhaler Lead Sponsor: GB002, Inc., a wholly owned subsidiary of Gossamer Bio, Inc. Planned Enrollment: 74 participants